Lenabot 25 Capsule contains Lenalidomide 25mg, an immunomodulatory and anticancer medication indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and certain hematologic malignancies. It helps in controlling abnormal cell proliferation and supporting immune system modulation.
Lenalidomide works by enhancing T-cell and natural killer (NK) cell activity, inhibiting angiogenesis, and inducing apoptosis in malignant cells, providing effective disease control and improving patient outcomes in oncology therapy.
For distributors and healthcare suppliers, Lenabot 25 Capsule is a high-demand oncology product, widely prescribed by hematologists, oncologists, and cancer care centers. The increasing need for effective multiple myeloma and hematologic malignancy treatments ensures steady market demand.
Adding Lenabot 25 Capsule to your oncology and immunomodulatory therapy segment creates strong opportunities in pharmacies, hospitals, cancer clinics, export markets, and third-party manufacturing. Its proven clinical efficacy, patient acceptance, and broad therapeutic application make it a valuable addition for pharmaceutical distribution.